Methods In total, 138 NAFLD patients aged 18-60 years were enrolled in the study. Patients
were randomized to one of the following treatments for 16 weeks: Group I (n= 68), sitagliptin …

Aim The aim of this case–control study was to assess the efficacy and safety of dipeptidyl
peptidase‐4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with non‐alcoholic fatty …

Background This study aimed to evaluate the efficacy and safety of sitagliptin for treating
Chinese patients with type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease …

The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-
alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned …

Purpose Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin
hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A …

Results Hemoglobin A1c (HbA1c) decreased by 0.7% after treatment (P< 0.001). While
HbA1c levels decreased by 0.4% in the low HbA1c (< 7.5%) group, those decreased by …

Results significant decreases of the plasma glucose and serum HbA1c, AST, ALT and γ-GTP
levels were observed after 4 months of treatment with sitagliptin. Conclusions In this study …

Results The change in HbA1c from the baseline following treatment with sitagliptin was-
0.47%(4 weeks),-0.73%(8 weeks) and-0.88%(12 weeks) in the type 2 DM patients with …

Background/purpose Dipeptidyl peptidase 4 (DPP-4) expression is directly associated with
hepatic lipogenesis and liver injury in nonalcoholic steatohepatitis (NASH). This study has …

AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic
parameters of non-alcoholic steatohepatitis (NASH). METHODS Twelve patients with biopsy …